Citizens JMP’s $80 target on CRSP

CRSP Crispr Therapeutics AG

$54.1 → $80 (+48%) by Sep 2027

Market Outperform · reiterates · said Sep 28, 2026 · 12-month default horizon

Open: judged on the close on Sep 28, 2027

The article this target came from

CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens

Investing.com · Sep 28, 2026

Citizens reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics shares

Citizens JMP’s track record → Crispr Therapeutics AG →

A fact about what Citizens JMP published, as reported by Investing.com, not a recommendation from Dalsna Finance; Citizens JMP is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.